Economic Benefits for Patients, Healthcare Providers Driving Biosimilar Sales Growth as Quality Worries Fade

Biosimilars are finally taking off. Japan’s first Enbrel (etanercept) follow-on has been hit by beyond-expected demand, while Sandoz/Kyowa Hakko Kirin’s Rituxan (rituximab) copy, also the country’s first, is likely to enjoy an upswing in its guidance. One thing they have...read more